In Stock Cell Lines
Homo sapiens (Human)
Skin
Adherent
The CYP2S1 Knockout HaCaT Cell Line is a CRISPR/Cas9-edited human keratinocyte model lacking functional CYP2S1, a cytochrome P450 enzyme induced by AhR ligands and involved in metabolizing all-trans retinoic acid and xenobiotics. This knockout allows dissection of retinoid signaling, oxidative stress, and xenobiotic detoxification in an epidermal context. HaCaT cells provide a robust, non-tumorigenic background for studying skin biology. The model is suitable for metabolism assays, oxidative stress studies, and cancer research, aiding investigations into psoriasis, squamous cell carcinoma, and drug toxicity.
DDX60 Knockout HT29 Polyclonal Cells
Cat. No. ARG14459
BOD1 Knockout jurkat Polyclonal Cells
Cat. No. ARG34023
CARD19 Knockout HAP1 Polyclonal Cells
Cat. No. ARG27474
PCYT2 Knockout A549 Polyclonal Cells
Cat. No. ARG10056
NPTN Knockout HCT116 Polyclonal Cells
Cat. No. ARG7039
Human Colonic Microvascular Endothelial Cells
Cat. No. ARP0051
The CYP2S1 Knockout HaCaT Cell Line is a CRISPR/Cas9-edited human keratinocyte model in which the CYP2S1 gene has been disrupted to create a stable loss-of-function system. This cell line enables precise investigation of CYP2S1-dependent metabolic and signaling pathways in an epidermal context, aiding mechanistic studies that require isogenic controls. It is suitable for a range of in vitro functional assays and comparative analyses with the parental HaCaT line.
HaCaT cells are a spontaneously immortalized, aneuploid, non-tumorigenic human keratinocyte line derived from adult skin. They maintain key characteristics of normal epidermal keratinocytes, including differentiation capacity and responsiveness to growth factors and environmental stimuli. Their robust proliferation and genetic stability in culture support reproducible, high-throughput experiments, making HaCaT a widely accepted model for studying skin physiology, xenobiotic metabolism, and oxidative stress responses.
CYP2S1 is a cytochrome P450 enzyme transcriptionally regulated by the aryl hydrocarbon receptor (AhR) upon binding of ligands such as polycyclic aromatic hydrocarbons and all-trans retinoic acid. It metabolizes all-trans retinoic acid and procarcinogens, linking AhR activation to detoxification and reactive oxygen species (ROS) production. CYP2S1 interacts with the electron donors NADPH-cytochrome P450 reductase and cytochrome b5, linking xenobiotic sensing, retinoid signaling, and redox homeostasis. Knockout of CYP2S1 thus provides a clean background to dissect these axes.
In keratinocytes, CYP2S1 loss impairs all-trans retinoic acid metabolism, modeling retinoid resistance relevant to psoriasis. Altered procarcinogen handling and ROS dysregulation may affect carcinogen susceptibility, relevant to squamous cell carcinoma. It also allows study of CYP2S1 in inflammatory skin diseases involving oxidative stress and retinoid signaling.
Applications include retinoic acid metabolism assays, CYP2S1 activity measurements, and AhR reporter assays. Standard validation employs western blotting, RT-qPCR, and DNA sequencing. Functional readouts include cell viability under oxidative stress (e.g., H2O2), intracellular ROS detection, and immunofluorescence. Global transcriptomic changes can be profiled by RNA-seq. These applications support research in skin biology, xenobiotic metabolism, drug toxicity, carcinogenesis, and oxidative stress. For further information or to discuss this product, please contact Ascent Research.
